Aclarion, Inc. (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company, announced on May 6, 2026, that its compensation committee granted an inducement stock option to Daniel Keefe, the newly hired Commercial Director for the Western U.S. The option to purchase 17,000 shares of common stock was granted on May 5, 2026, at an exercise price of $3.20 per share, equal to the closing price on that day. This award, made in accordance with Nasdaq Listing Rule 5635(c)(4), serves as a material inducement for Mr. Keefe to join the company.
The stock option vests over a four-year period, with one-fourth vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal monthly installments over the subsequent three years, contingent on continued employment. The option has a 10-year term and is governed by an inducement stock option agreement.
This expansion of the commercial team reflects increasing demand for Aclarion's Nociscan platform, which has experienced triple-digit growth in utilization. Nociscan is a Software-as-a-Service (SaaS) platform that uses magnetic resonance spectroscopy (MRS), proprietary signal processing, biomarkers, and augmented intelligence to help physicians identify painful discs in the lumbar spine, thereby improving treatment success rates for chronic low back pain. The platform noninvasively distinguishes between painful and nonpainful discs by analyzing chemical biomarkers from MRI data.
The appointment of a dedicated director for the Western U.S. underscores Aclarion's focus on scaling its commercial operations to meet growing adoption. The company's forward-looking statements highlight expectations for continued demand, though risks remain as detailed in its filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2025. For more information, visit www.aclarion.com.
This strategic hire aligns with Aclarion's mission to optimize clinical treatments for chronic low back pain, a condition affecting millions. By expanding its commercial footprint, the company aims to make Nociscan more accessible to physicians across the country, potentially reducing the need for invasive diagnostic procedures and improving patient outcomes.
